Pancreatic Cancer Research

Journal articleClin Cancer Res2026

Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies.

Journal
Clin Cancer Res
Published
1 May 2026
Citations
2

These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

abstract license unknown

Purpose ARID1A is frequently mutated in cancer. Motivated by the preclinical synthetic lethality between ARID1A loss and ataxia telangiectasia and Rad3-related (ATR) inhibition, we performed an investigator-initiated phase II study of the ATR inhibitor (ATRi) ceralasertib in ARID1A-deficient solid tumors (NCT03682289). … Excerpt only: this text is the publisher’s. Read it in full at the source.